统一急性肾损伤与急性肾病流行病学定义后四地域人群研究结果可比
年龄性别标化发病率在不同地区和年份间相似,范围为134.3-162.4例/万人年;符合48小时或7天AKI肌酐标准患者的标化1年死亡率相似(30.4%-38.5%)。作者认为统一分析方法可提高AKI研究的可比性。
要点
- 采用统一KDIGO肌酐定义后,四地域AKI/AKD标化发病率相似,范围134.3-162.4例/万人年。
- 符合48小时或7天AKI肌酐标准者标化1年死亡率相似,各队列为30.4%-38.5%。
- 使用90天前基线肌酐判定AKI/AKD者标化1年死亡率较低,各队列为21.0%-25.5%。
核心结论
- 基于KDIGO标准的AKI和AKD发病率和预后在3个高收入国家间一致,前提是实验室检测捕获完整、肌酐定义在90天周期内一致实施、并对人群年龄和性别进行调整。
研究设计与样本
- 使用来自加拿大、丹麦和英国的4个人群数据集,采用统一分析方法纳入KDIGO肌酐定义及AKI/AKD标准子集。
主要发现
- AKI或AKD的年龄性别标化发病率在不同地区和年份间相似,范围为134.3-162.4例/万人年。
- 符合KDIGO 48小时或7天AKI肌酐标准患者的标化1年死亡率各队列为30.4%-38.5%,与使用8-90天内基线肌酐判定AKI/AKD者的32.0%-37.4%相当。
- 使用90天前基线肌酐判定AKI/AKD患者的标化1年死亡率较低,各队列为21.0%-25.5%。
关键数值与推荐
- AKI或AKD年龄性别标化发病率范围为134.3-162.4例/万人年。
- 符合KDIGO 48小时或7天AKI肌酐标准者标化1年死亡率为30.4%-38.5%。
- 使用8-90天内基线肌酐判定AKI/AKD者标化1年死亡率为32.0%-37.4%。
- 使用90天前基线肌酐判定AKI/AKD者标化1年死亡率为21.0%-25.5%。
临床怎么用
- 作者认为这些方法应被一致应用,以提高AKI研究和临床报告的可推广性与可比性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is substantial variability in the reported incidence and outcomes of acute kidney injury (AKI). The extent to which this is attributable to differences in source populations versus methodological differences between studies is uncertain. We used 4 population-based datasets from Canada, Denmark, and the United Kingdom to measure the annual incidence and prognosis of AKI and acute kidney disease (AKD), using a homogenous analytical approach that incorporated KDIGO creatinine-based definitions and subsets of the AKI/AKD criteria. The cohorts included 7 million adults ≥18 years of age between 2011 and 2014; median age 59-68 years, 51.9-54.4% female sex. Age- and sex-standardised incidence rates for AKI or AKD were similar between regions and years; range 134.3-162.4 events/10,000 person years. Among patients who met either KDIGO 48-hour or 7-day AKI creatinine criteria, the standardised 1-year mortality was similar (30.4%-38.5%) across the cohorts, which was comparable to standardised 1-year mortality among patients who met AKI/AKD criteria using a baseline creatinine within 8-90 days prior (32.0%-37.4%). Standardised 1-year mortality was lower (21.0%-25.5% across cohorts) among patients with AKI/AKD ascertained using a baseline creatinine >90 days prior. These findings illustrate that the incidence and prognosis of AKI and AKD based on KDIGO criteria are consistent across 3 high-income countries when capture of laboratory tests is complete, creatinine-based definitions are implemented consistently within but not beyond a 90-day period, and adjustment is made for population age and sex. These approaches should be consistently applied to improve the generalizability and comparability of AKI research and clinical reporting.
引用
- Sawhney S, Bell S, Black C, et al. Harmonization of epidemiology of acute kidney injury and acute kidney disease produces comparable findings across four geographic populations. Kidney Int. 2022. PMID: 35398477. doi:10.1016/j.kint.2022.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。